Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
Treatments like semaglutide and tirzepatide have helped many people lose significant weight, improve metabolic health, and regain confidence after years of struggling with traditional dieting
What do GLP-1 medications do to your nutrition needs
00:13:27 Vickie Danaher Because of oral semaglutides strict administration requirements, patients who miss a dose should skip the missed dose and just take the next dose the following day
Similarly, we studied 17,733 patients prescribed liraglutide who achieved a weight loss of at least five pounds while on the medication
